Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma

BACKGROUND: Vorinostat (suberoylanilide hydroxamic acid, SAHA), an inhibitor of class I and II histone deacetylases, has been approved for the treatment of cutaneous T-cell lymphoma. In spite of emerging information on the effect of vorinostat in many types of cancer, little is yet known about this...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wozniak, Magdalena B., Villuendas, Raquel, Bischoff, James R., Aparicio, Carmen Blanco, Martínez Leal, Juan F., de La Cueva, Paloma, Rodriguez, Ma Elena, Herreros, Beatriz, Martin-Perez, Daniel, Longo, Maria I., Herrera, Marta, Piris, Miguel Á., Ortiz-Romero, Pablo L
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2010
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2857191/
https://ncbi.nlm.nih.gov/pubmed/20133897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.013870
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados